Core Viewpoint - The successful listing of Beixin Life Technology Co., Ltd. on the STAR Market marks the first successful IPO under the "fifth set of standards" for innovative medical device companies, highlighting the potential for growth in the cardiovascular precision diagnosis and treatment sector [1][4]. Company Overview - Beixin Life focuses on the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, with 17 approved and in-development products as of September 30, 2025 [4]. - The company has incurred significant losses due to high R&D and market promotion costs, with a cumulative undistributed profit of -690 million yuan as of June 30, 2025, but is now moving towards profitability as commercialization progresses [4][7]. Financial Performance - Revenue for Beixin Life is projected to grow significantly, with estimates of 520 million to 560 million yuan for 2025, representing a year-on-year increase of 64.24% to 76.88%, and a net profit of 78 million to 88 million yuan, marking a turnaround from previous losses [7]. - The company raised a total of 999 million yuan in its IPO, with a net amount of 899 million yuan allocated primarily for the construction of an interventional medical device industrial base and R&D [7]. R&D and Innovation - Beixin Life has consistently increased its R&D investment, totaling 389 million yuan over the past three years, with a workforce of 100 R&D personnel, over 40% of whom hold advanced degrees [6]. - The company has launched 11 products to market and has 6 products in development, with its core IVUS and FFR systems having received regulatory approval and achieving significant market share [6][8]. Market Position and Competition - The IVUS system is the first domestically approved 60MHz high-definition product and has captured a leading market position, while the FFR system holds a 30.6% market share shortly after its launch [6][10]. - Despite the competitive landscape, with established international players and other domestic manufacturers, the market for IVUS and FFR is expected to grow significantly, with projections indicating a compound annual growth rate of approximately 19.4% to 21.1% through 2030 [10]. Challenges and Risks - Beixin Life faces challenges from increasing competition and potential risks related to product commercialization and R&D failures, as well as pressures from centralized procurement policies that could impact pricing and market share [9][10]. - The company’s stock is currently trading at a higher price-to-sales ratio compared to industry peers, which may pose risks for investors if market conditions change [11].

Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. (Beixin Life) officially listed on the Sci-Tech Innovation Board on February 5, 2026, under the stock code "688712.SH," marking it as the first medical device company to successfully list under the new fifth set of standards since its restart and the first medical device company to list in 2024 [3]. Group 1: Company Overview - Beixin Life is the first domestic medical device company with a product portfolio that includes intravascular functional flow reserve (FFR) and intravascular ultrasound (IVUS) [3]. - The company has received investments from several well-known institutions, including Qiming Venture Partners, which led its Series C financing in 2020 and continued to support its development in Series D financing [4]. Group 2: Investment Insights - Qiming Venture Partners holds over 6% of Beixin Life's shares prior to the IPO, indicating its role as a major institutional investor [4]. - The firm has a strong interest in the cardiovascular and other medical device sectors, having a history of successful cases in these fields [4]. Group 3: Strategic Approach - Beixin Life's strategy focuses on building a robust product portfolio and company capabilities rather than merely pursuing rapid registration, emphasizing the creation of differentiated and competitive products [5]. - The company has maintained this strategy for over a decade, which has instilled confidence among shareholders [5]. Group 4: Future Expectations - Post-IPO, Beixin Life is expected to continue strengthening its product line in the coronary field and expand into high-potential new areas such as electrophysiology [5]. - There is significant untapped international market potential for Beixin Life's products, with plans for deeper internationalization following the IPO [5]. Group 5: Market Context - In 2025, Qiming Venture Partners invested in over 30 projects in the medical innovation sector, contributing more than 3 billion yuan, despite a cautious investment environment in the medical sector [5]. - The firm maintains strong confidence in the fundamentals of Chinese medical innovation, believing that China's clinical experience, engineering teams, and entrepreneurial spirit can foster globally competitive medical device products [6].

红杉中国董事总经理曹弋博（左）与北芯生命创始人、董事长兼CEO宋亮博士在上市仪式 现场。 本文为IPO早知道原创 作者｜ Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，深圳北芯生命科技股份有限公司（以下简称"北芯生命"）于2026年2月5日正式 以"688712.SH"为股票代码在上海证券交易所科创板挂牌上市。 值得一提的是， 北芯生命是重启科创板第五套标准后，该标准下第三家、医疗器械行业首家成功上 市企业，也是2024年以来首家在科创板成功上市的医疗器械企业。 作为国内首家拥有血管内功能学血流储备分数（FFR）及影像学血管内超声（IVUS）产品组合的国 产医疗器械公司，北芯生命自成立以来已获得红杉中国等多家知名机构的投资。 其中， 红杉中国于2018年领投了北芯生命的B轮融资且在后续各轮融资中持续支持。IPO前，红杉 中国持有北芯生 命超10%的股份，为公司最大机构投资方，红杉中国董事总经理曹弋博担任北芯生 命董事，也是在北芯生命服务时间最长的投资人董事 曹弋博表示："北芯生命是红杉中国深耕心血管精准诊疗赛道的重要战略布局。我们认为，真正的国 产替代不应止步于复制，而在于超越 ...

Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking it as the first medical device company to do so in 2024 and the first under the new fifth set of standards for the board [2][12]. Company Overview - Established in 2015, Beixin Life focuses on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, aiming to transform clinical practices [6][10]. - The company has launched 11 products and has 6 more in development, covering various categories including IVUS systems and FFR systems [6]. Product Highlights - The core product, the IVUS system, is the first domestically developed 60MHz high-definition IVUS product approved by the National Medical Products Administration, featuring high definition, speed, and intelligence [7]. - The FFR system is recognized as the gold standard for PCI treatment guidance and has received high-level recommendations in multiple domestic and international guidelines [7]. - Beixin Life's PFA system is the first in China to be included in breakthrough clinical research at the European Society of Cardiology [8]. Market Impact - The successful launch of Beixin Life's products has filled a significant gap in the domestic market, previously reliant on imported products for precise cardiovascular diagnosis [7][10]. - The company has established a presence in over 30 provinces in China and has clinical applications in more than 1,000 hospitals globally, including in Belgium, Germany, and Italy [8]. Innovation and R&D - Beixin Life emphasizes long-term independent research and technological innovation, having developed four core technology platforms for medical devices [10]. - The company holds 185 domestic and international patents, including 86 invention patents and 14 PCT international patent applications [10]. Future Prospects - The listing is seen as a new starting point for Beixin Life, enabling it to accelerate development in innovation, global market expansion, and capital collaboration [12]. - The cardiovascular intervention field is expected to see significant growth, driven by increasing clinical needs and technological advancements [11]. Investment and Support - Major institutional investors include Sequoia China and Qiming Venture Partners, who have expressed confidence in Beixin Life's innovative capabilities and market potential [14][15]. - The company has received continuous support from its investors, focusing on building a strong product portfolio and enhancing its competitive edge in the market [15][17].

Core Viewpoint - North Chip Life Technology Co., Ltd. successfully listed on the Sci-Tech Innovation Board, marking a significant milestone for the company and the medical device industry in China, with strong investor interest reflected in a subscription multiple of 4595.20 times during the IPO process [1][7]. Company Overview - North Chip Life is the first medical device company to successfully list under the fifth set of standards of the Sci-Tech Innovation Board, emphasizing support for innovative high-end manufacturing enterprises with original technology [1][2]. - The company is recognized for its core products, the intravascular ultrasound (IVUS) diagnostic system and the fractional flow reserve (FFR) measurement system, which are the first domestically approved products in China [3][4]. Market Potential - The market for PCI (Percutaneous Coronary Intervention) procedures in China has surpassed one million annually, yet the penetration rate of IVUS and FFR products remains low, indicating significant growth potential [4][9]. - The company’s FFR system captured 30.6% of the domestic market share in its first year, while the IVUS system has reached approximately 1,000 hospitals since its launch in 2022 [4][5]. Financial Projections - North Chip Life projects revenue for 2025 to be between 520 million to 560 million yuan, representing a year-on-year increase of 64.24% to 76.88%, with net profit expected to reach 78 million to 88 million yuan, indicating a nearly threefold growth [1][10]. R&D and Innovation - The company has invested 389 million yuan in R&D from 2022 to 2024, with R&D expenses projected to account for 35.65% of revenue in 2024 [5][6]. - North Chip Life holds 185 domestic and international patents, with a strong focus on developing a comprehensive product line that includes 17 products across five categories [6]. Recognition and Achievements - The company has received multiple accolades, including recognition as a national "little giant" enterprise and awards for its innovative medical devices, further establishing its credibility in the market [6].

Group 1 - The core viewpoint of the article is that Beixin Life (688712) has been listed on the Shanghai Stock Exchange, focusing on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [1] - Beixin Life is recognized as a national high-tech enterprise dedicated to developing transformative solutions for cardiovascular disease diagnosis and treatment [1] - As of September 30, 2025, the company has no single shareholder holding more than 30% of the shares, indicating a relatively dispersed ownership structure [1] Group 2 - The largest shareholder, Song Liang, directly holds 16.1530% of the company's shares and controls an additional 13.4140% through partnerships, giving him a total voting power of 29.5670% [1] - After the recent issuance, Song Liang's direct shareholding is 13.9450%, with an additional 11.5804% controlled through partnerships, resulting in a total voting power of 25.5254% [1] - The total amount raised from the issuance is 998.64 million yuan, with a net amount of 898.89 million yuan allocated for the construction of an interventional medical device industrialization base, R&D projects, and to supplement working capital [2]

每经AI快讯，今日无新股申购；有1只新股上市，为科创板的北芯生命。 ...

| | 北芯生命(科创板,688 | | --- | --- | | 发行价格 | 17.52元 | | 智签率 | 0.03% 询价 | | 总市值 | 73.06亿 | | 发行市盈率 | 行业 | | 业务及亮点 | 1、公司是我国心血管精准介入解决方案的行业标 内首创，推动冠状动脉疾病临床精准诊断国产化。 | | | 2、核心产品FFR测量系统2021年占据30.6%国内 | | | 适应症市占率10.4%（国内第二），多款产品海外 | | | 3、产品管线丰富，7个在研项目推进迭代升级， | | | 冲电场消融系统进入临床试验阶段。 | | | 4、实控人宋亮博士拥有逾18年相关研发经验,公 | | | 项资质认证,核心产品获科技进步奖及优秀国产 | *免责声明：文章内容仅供参考，不构成投资建议 *风险提示：股市有风险，入市需谨慎 ...

Group 1: Company News - JinkoSolar announced that it has not engaged in any cooperation with Elon Musk's team regarding space photovoltaic projects, despite market speculation. The company confirmed that it has not signed any agreements or received orders related to this area [4][5] - High Measurement Technology also clarified that it has not initiated any space photovoltaic business and has not engaged with Musk's team, stating that there has been no impact on its operational performance [4][5] - Guosheng Technology reported that it does not provide HJT photovoltaic systems for commercial space companies and is not involved in space photovoltaic business [5] - Shuangliang Energy stated that it has not confirmed any revenue related to commercial space projects in the past two years and emphasized the uncertainty surrounding the commercialization of space photovoltaic technology [5] - Ruixin Technology is planning to acquire control of Wuhu Deheng Automotive Equipment Co., Ltd. through a share issuance and cash payment, leading to a stock suspension starting February 5 [6] - Chang'an Automobile announced a share repurchase plan with a total amount between 1 billion and 2 billion yuan, aimed at reducing registered capital [7] - Shengxin Lithium Energy plans to acquire a 13.93% stake in Huirong Mining for 1.26 billion yuan, which will result in full control of the mining company [7] Group 2: Industry News - The People's Bank of China emphasized the need for quality financial services in key strategic areas during a recent meeting, focusing on the economic and financial landscape for the 14th Five-Year Plan period [2] - The Ministry of Industry and Information Technology highlighted the importance of integrating artificial intelligence with manufacturing, aiming to strengthen application foundations and promote international cooperation in the AI sector [3] - The Supreme People's Court discussed its role in optimizing the business environment and protecting the rights of private enterprises, indicating a commitment to support the unified national market [2]

2026年1月30日 深圳北芯生命科技股份有限公司（以下简称"北芯生命"、"发行人"或"公司"）首次公开发行人民币普通 股（以下简称"本次发行"）并在科创板上市的申请已经上海证券交易所（以下简称"上交所"）科创板上 市委员会审议通过，并已经中国证券监督管理委员会（以下简称"中国证监会"）同意注册（证监许可 〔２０２５〕２７９０号）。《深圳北芯生命科技股份有限公司首次公开发行股票并在科创板上市招股 说明书》在上海证券交易所网站（网址ｗｗｗ．ｓｓｅ．ｃｏｍ．ｃｎ）和符合中国证监会规定条件网 站（中国证券网，网址ｗｗｗ．ｃｎｓｔｏｃｋ．ｃｏｍ；中证网，网址ｗｗｗ．ｃｓ．ｃｏｍ．ｃ ｎ；证券时报网，网址ｗｗｗ．ｓｔｃｎ．ｃｏｍ；证券日报网，网址ｗｗｗ．ｚｑｒｂ．ｃｎ；经济 参考网，网址ｗｗｗ．ｊｊｃｋｂ．ｃｎ；中国金融新闻网，网址ｗｗｗ．ｆｉｎａｎｃｉａｌｎｅｗ ｓ．ｃｏｍ．ｃｎ；中国日报网，网址ｃｎ．ｃｈｉｎａｄａｉｌｙ．ｃｏｍ．ｃｎ）披露，并置备于 发行人、上交所、本次发行保荐人（主承销商）中国国际金融股份有限公司的住所，供公众查阅。 ■■ 发行人：深圳北芯生命科技股份有限公司 保荐人（主承销商）：中国国际金融股 ...